<SUBMISSION>
<ACCESSION-NUMBER>0000914062-08-000089
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>4
<PERIOD>20080207
<ITEMS>8.01
<ITEMS>9.01
<FILING-DATE>20080212
<DATE-OF-FILING-DATE-CHANGE>20080212
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>CRYOLIFE INC
<CIK>0000784199
<ASSIGNED-SIC>3841
<IRS-NUMBER>592417093
<STATE-OF-INCORPORATION>FL
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>001-13165
<FILM-NUMBER>08596556
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>1655 ROBERTS BOULEVARD N W
<STREET2>STE 142
<CITY>KENNESAW
<STATE>GA
<ZIP>30144
<PHONE>7704193355
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>1655 ROBERTS BOULEVARD N W
<STREET2>STE 142
<CITY>KENNESAW
<STATE>GA
<ZIP>30144
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cryolife8k20708.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html>

  <head>
    <title>cryolife8k20708.htm</title>
<!-- Licensed to: AGG-->
<!-- Document Created using EDGARizer 4.0.3.0 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff">
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="top" width="80%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">UNITED
      STATES</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">SECURITIES
      AND EXCHANGE COMMISSION</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman; FONT-VARIANT: small-caps">washington,
      d.c. 20549</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div align="center">
      <table cellpadding="0" cellspacing="0" width="21%">

          <tr>
            <td valign="top" width="21%" style="BORDER-TOP: black 0.5pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman">FORM
                8-K</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CURRENT
      REPORT</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PURSUANT
      TO SECTION 13 OR 15(d) OF THE</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITIES
      EXCHANGE ACT OF 1934</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date
      of Report (Date of earliest event reported):&#160;&#160;February 7,
      2008</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">_______________________</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">CRYOLIFE,
      INC.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Exact
      name of registrant as specified in its charter)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">_________________________</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Florida</font></div>
            </td>
            <td valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1-13165</font></div>
            </td>
            <td valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">59-2417093</font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(State
                or Other Jurisdiction</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">of
                Incorporation)</font></div>
            </td>
            <td valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Commission
                File Number)</font></div>
            </td>
            <td valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(IRS
                Employer</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Identification
                No.)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1655
      Roberts Boulevard, N.W., Kennesaw, Georgia&#160;&#160;30144</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive office) (zip code)</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Registrant's
      telephone number, including area code: (770) 419-3355</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">_____________________________________________________________</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Former
      name or former address, if changed since last report)</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">_________________________</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 18pt"></font>Check
      the appropriate box below if the
      Form 8-K filing is intended to simultaneously satisfy the filing obligation
      of
      the registrant under any of the following provisions (see General Instruction
      A.2. below):</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Written
                communications pursuant to Rule 425 under the Securities Act (17
                CFR
                230.425) </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Soliciting
                material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
                240.14a-12) </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pre-commencement
                communications pursuant to Rule 14d-2(b) under the Exchange Act (17
                CFR
                240.14d-2(b)) </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pre-commencement
                communications pursuant to Rule 13e-4(c) under the Exchange Act (17
                CFR
                240.13e-4(c)) </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="top" width="80%" style="BORDER-TOP: black 2.25pt solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
          </tr>

      </table>
    </div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Section
      8&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other Events</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Item
      8.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other Events.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>On
      February 7, 2008, CryoLife, Inc.
      (&#8220;CryoLife&#8221; or the &#8220;Company&#8221;) issued a press release announcing that the Food
      and Drug Administration (&#8220;FDA&#8221;) notified CryoLife that it has received 510(k)
      clearance from the FDA for its CryoValve SG pulmonary heart valve processed
      with
      the Company&#8217;s proprietary SynerGraft technology.&#160;&#160;CryoLife hereby
      incorporates by reference herein the information set forth in its Press Release
      dated February 7, 2008, a copy of which is attached hereto as Exhibit
      99.1</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>Except
      for the historical information
      contained in this report, the statements made by CryoLife are forward-looking
      statements that involve risks and uncertainties. All such statements are subject
      to the safe harbor created by the Private Securities Litigation Reform Act
      of
      1995.&#160; </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">These
      statements include those regarding anticipated effectiveness, benefits and
      indications for use of CryoValve SG as well as the timing of use of the
      SynerGraft technology. These future events may not occur as and when expected,
      if at all, and, together with the Company's business, are subject to various
      risks and uncertainties.&#160;&#160;These risks and uncertainties include that
      CryoValve SG may not perform as well as expected or provide all of the benefits
      anticipated, the Company may not be able to begin processing the majority of
      its
      pulmonary valves by the anticipated time, nor may the first shipments of
      CryoValve SG occur as expected,&#160;&#160;and other risk factors detailed in
      CryoLife's Securities and Exchange Commission filings, including CryoLife's
      Form
      10-K filing for the year ended December 31, 2006, its most recent Form 10-Q,
      and
      the Company's other SEC filings. The Company does not undertake to update its
      forward-looking statements.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">Section
      9</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; COLOR: #000000">Financial Statements
      and
      Exhibits</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">Item
      9.01(c)</font>&#160;&#160;&#160;<font style="DISPLAY: inline; COLOR: #000000">Exhibits.</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">(a)
      Financial
      Statements.</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; COLOR: #000000">Not
      applicable.</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">(b)
      Pro Forma Financial
      Information.</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; COLOR: #000000">Not
      applicable.</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">(c)
      Shell Company
      Transactions.</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; COLOR: #000000">Not
      applicable.</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">(d)
      Exhibits.</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div align="center">
      <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top">
            <td width="3%" style="WIDTH: 144pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td width="20%" style="WIDTH: 144pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit
              Number</font></font></td>
            <td width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Description</font></font></td>
          </tr>
          <tr valign="top">
            <td width="3%" style="WIDTH: 144pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td width="20%" style="WIDTH: 144pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
          </tr>
          <tr valign="top">
            <td width="3%" style="WIDTH: 144pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td width="20%" style="WIDTH: 144pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.1</font></div>
            </td>
            <td width="77%">
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Press
                release dated February 7, 2008 </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIGNATURES</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, CryoLife, Inc.
      has
      duly caused this report to be signed on its behalf by the undersigned hereunto
      duly authorized.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td align="left" valign="top" width="40%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CRYOLIFE,
                INC.</font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
          </tr>
          <tr>
            <td valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
          </tr>
          <tr>
            <td valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
          </tr>
          <tr>
            <td valign="top" width="40%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date:&#160;&#160;February
                11, 2008</font></div>
            </td>
            <td valign="top" width="40%" style="BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: -45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:&#160;&#160;&#160;&#160;&#160;&#160;
                <font style="DISPLAY: inline">/s/ D. A. Lee</font></font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td valign="top" width="40%">
              <div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: -45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name:
                D. Ashley Lee</font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td valign="top" width="40%">
              <div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: -45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title:&#160;&#160;
                Executive Vice President, Chief</font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td valign="top" width="40%" style="PADDING-LEFT: 0pt">
              <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: -45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Operating
                Officer and Chief</font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td valign="top" width="40%" style="PADDING-LEFT: 0pt">
              <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: -45pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Financial
                Officer</font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br></body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>cryolife8k20708ex99.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>

  <head>
    <title>cryolife8k20708ex99.htm</title>
<!-- Licensed to: AGG-->
<!-- Document Created using EDGARizer 4.0.3.0 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit
      99.1</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><img src="cryolifesyner1.jpg" alt=""></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FOR
      IMMEDIATE RELEASE</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="59%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Media
                Contacts:</font></div>
            </td>
            <td valign="top" width="21%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
          </tr>
          <tr>
            <td valign="top" width="59%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td valign="top" width="21%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
          </tr>
          <tr>
            <td align="left" valign="top" width="59%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">D.
                Ashley Lee</font></div>
            </td>
            <td align="left" valign="top" width="21%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Katie
                Brazel</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="59%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Executive
                Vice President, Chief Financial</font></div>
            </td>
            <td align="left" valign="top" width="21%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fleishman
                Hillard</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="59%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Officer
                and Chief Operating Officer</font></div>
            </td>
            <td align="left" valign="top" width="21%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Phone:
                404-739-0150</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="59%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Phone:
                770-419-3355</font></div>
            </td>
            <td valign="top" width="21%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">CryoLife
      Receives FDA 510(k) Clearance for SynerGraft<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">&#174;</font>
      Processed Human Pulmonary Heart Valves</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ATLANTA&#8230;(February
      7, 2008)&#8230;CryoLife, Inc., (NYSE: CRY) a biomaterials, medical device and tissue
      processing company, today announced that it has received 510(k) clearance from
      the Food and Drug Administration (FDA) for its CryoValve<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">&#174;</font>
      SG
      pulmonary human heart valve processed with the Company&#8217;s proprietary SynerGraft
      technology.&#160;&#160;CryoLife&#8217;s proprietary SynerGraft technology is designed
      to remove allogeneic donor cells and cellular remnants from the valve without
      compromising the integrity of the underlying collagen matrix.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      CryoValve SG pulmonary human heart valve is indicated for the replacement of
      diseased, damaged, malformed or malfunctioning native pulmonary
      valves.&#160;&#160;The valve can be used in conjunction with right ventricular
      outflow tract reconstruction procedures (RVOT), commonly performed in children
      with congenital heart defects. In addition, the valve can be used for pulmonary
      valve replacement during the Ross Procedure, an operation in which a patient&#8217;s
      defective aortic valve is removed and replaced with his own pulmonary
      valve.&#160;&#160;The CryoValve SG is then surgically implanted in place of the
      removed native pulmonary valve.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>&#160;&#8220;CryoValve
      SG may offer an
      attractive valve replacement option for many children born with heart defects,&#8221;
said Steven G. Anderson, CryoLife&#8217;s president and chief executive
      officer.&#160;&#160;&#8220;CryoValve SG may also be a good option for patients who
      have undergone valve replacement surgery as young children, but may require
      another valve replacement as they&#8217;ve grown into adulthood.&#8221;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">--</font><font style="DISPLAY: inline; COLOR: #000000">more--</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><img src="cryolifesyner2.jpg" alt=""></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>&#8220;Children
      born with heart defects often
      face frequent and challenging surgeries,&#8221; stated John W. Brown, M.D., professor
      of Cardiothoracic Surgery, Indiana University School of Medicine, Indianapolis,
      Ind. &#8220;For certain heart defects, CryoValve SG may give these kids a great
      opportunity to live active, normal lives. As a surgeon, I&#8217;m very excited to be
      able to offer them and their families this treatment option.&#8221;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At
      FDA&#8217;s
      request, CryoLife is planning a post-clearance study to seek evidence for the
      potential and implied long-term benefits of the SynerGraft
      process.&#160;&#160;Data to be collected is expected to include long-term safety
      and hemodynamic function, immune response, and explant analysis. CryoLife
      believes that this information may help it ascertain whether the SynerGraft
      process reduces the immunogenicity of the transplanted heart valve and
      recellularizes with the recipients own cells.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CryoLife
      will be using the SynerGraft technology for the majority of its pulmonary valve
      processing and anticipates that the first CryoValve SG may be available for
      shipment late in the first quarter of 2008.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">About
      CryoLife, Inc.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Founded
      in 1984, CryoLife, Inc. is a leader in the processing and distribution of
      implantable living human tissues for use in cardiac and vascular surgeries
      throughout the United States and Canada. The Company's BioGlue<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">&#174;</font>
      Surgical
      Adhesive is FDA approved as an adjunct to sutures and staples for use in adult
      patients in open surgical repair of large vessels. BioGlue is also CE marked
      in
      the European Community and approved in Canada and Australia for use in soft
      tissue repair. The Company also distributes the CryoLife-O'Brien<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">&#174;</font>
      stentless porcine heart valve, which is CE marked for distribution within the
      European Community.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Statements
      made in this press release that look forward in time or that express
      management's beliefs, expectations or hopes are forward-looking statements
      within the meaning of the Private Securities Litigation Reform Act of
      1995.&#160;&#160;These statements include those regarding anticipated
      effectiveness, benefits and indications for use of CryoValve SG as well as
      the
      timing of use of the SynerGraft technology. These future events may not occur
      as
      and when expected, if at all, and, together with the Company's business, are
      subject to various risks and uncertainties.&#160;&#160;These risks and
      uncertainties include that CryoValve SG may not perform as well as expected
      or
      provide all of the benefits anticipated,<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>the Company may not
      be
      able to begin processing the majority of its pulmonary valves by the anticipated
      time, nor may the first shipments of CryoValve SG occur as expected,<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font> and other risk factors
      detailed in CryoLife's Securities and Exchange Commission filings, including
      CryoLife's Form 10-K filing for the year ended December 31, 2006, its most
      recent Form 10-Q, and the Company's other SEC filings. The Company does not
      undertake to update its forward-looking statements.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      additional information about the company, visit CryoLife&#8217;s Web
      site:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #0000ff; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #0000ff; TEXT-DECORATION: underline">http://www.cryolife.com</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">###</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br></body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>cryolifesyner1.jpg
<TEXT>
begin 644 cryolifesyner1.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#__@`<4V]F='=A<F4Z($UI8W)O<V]F="!/
M9F9I8V7_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-#AT5%A$8(Q\E)"(?(B$F
M*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_P``+"`!J`10!`1$`_\0`
M'``!``(#`0$!``````````````4&`P0'`@$(_\0`1A```0,#`P,"!`0"!`D-
M`````0(#!``%$082(0<3,4%1%")A<14R@9$CH0@60K$7)#,T<H*2LL$E-C=%
M4E1B=**CPM'2_]T`!``H_]H`"`$!```_`.RTJB:OZJV[2.H&[0]`>DJVI6\X
MA8`;"O&!ZG'/I5H&I+*;G'M@N3'QLE&]IC=\Y&,^/3CWK3E:WT^Q;+E.9N#4
MH6P*[[3*LK!!QC'WXSXK0T)U!AZY1+#,-R(_%*2MM:@H%*LX(.!['BK=2L$R
M;%MT1R7-D-QV&QE;CJ@E*1]S5#N'6W24-XML?&3<'&]ED!)^VXBIG2_4:P:N
MF_!6U<@20T75-NM;=J00#SX]15JI2E*5\4=J2K!.!G`\FJG9>I>G+_=V[5;U
MRG)3A/RF.H!.!DDGT'%6VHU.HK*N\FSIN<95P'F,'!O\9QCWQZ5ZN]^M-A82
M]=;@Q#0LX3W5X*C]!Y-?+)?K=J*"9UK?[\<.*;[FTIR1YQFI&M2=<X5L2A4R
M0AKN'"`<DJ/K@#DUFC2F)L=,B,\AUI7A:#D5H7W4EITTPT_=Y?PK3R]B%E"E
M#=C..`<5ELU\MNH(/QMJE"3'WE'<"2!D>1R![UOTI2E*4I7#=>79RY:@<NLO
M0:G(5H=#,B1(*TEP9P`2D@8R>//GZUBZ3*LK.N7V;@PE^9('>MLMTYXY.`/&
MXC]MI%0NJ9VFH_4*5(MMN;-MA@I>82LA$MSD$#V!)]/1)-?_T-GI5<9-JN*;
M.[I!RWBYH^)1+;W$%&"1N*R>.<#!]?'-=<KX2`,DX`K\YZUU'=.HNLDVBUE3
MD1+Q9AL)5A*R/+A^_)SZ"K]9^A=ACPT_BTF3,DD#>6E]M"3[`8S^]2^F>F=O
MT=J9R\6Z:\J.J,MI3#PW%.2DY"AZ?+XQ4Q&UYI267`S?H9[2"M>7-NU(\GFO
M#/4#2S\9^4W=VS&CN);<?*%!`4H$@9Q]#4A9]1V>_ATVFX,S`SCN=HYVYSC/
M[&LUVO-NL4,2[I+;BL%01W'/&3X'\JUH&JK#=(TB5"NL=Z/&`+SH5A#>?<G@
M5%_X3=%_$=C\?C[LXSA6W_:QBK+%E1YL=$F(^V^RX,H<;4%)4/H17`.E'\+J
MPIL#C$A/VQG_`.J_0E<<BZ)L\7J8;R-7V\M-S%R?A^\.^%@E2D'GP#G)]AXJ
MJ:_EQ]2]4RPNZM&WJ<981)2L*;:;(&X@^."2:[5H:S6?3]@7$LUS$^'WU++Q
M<2O:K`R,IX],_K65[7>E&)1C.:@@)=!P1W@0#]_%1^K+$]J%461#/Q,1U*4N
MJCN([B4A6X*;*OE()P#SZ#VJ3TE:9-HM'9EI0AU:@HH2K=C"$IR3ZJ.W<?J?
M7S53ZZ(W:&85@?+.1_NJK9Z*9_P>M?\`F7?[Q5PGWRT6M81/N<2*L^$O/)0?
MV)K:CRH\QD/17VWVE>%M+"DG]17M:T-H*W%)0A(R5*.`!46C56G7'BRB^VY3
MB3@I$I&?[ZE00H`@@@\@BOM*5S#6W4JU3[1=+)89TL79OAIQA"D[BE0*@E0Y
M\!7[5$P^KEF5I)FRWRUW68M44,2G"E)[AQ@G)5G]:V-!=+H%PM$*\7.5(>:4
M2["9;46E-H).-RASGUP",'/G-:&LM`6;1C]NNKBGG[$W*_CQ$@*>6LY(^8X!
M3\H'/@9\YK[JSJ]'U!8/PW3C%TASW'4;%(PD[1Z#8HGGVJ]Z9Z@V"[2XUB1/
M4Y<DLI2O>@[7%I3\P"CY/!^^*G=2N.,Z6NSK)(<1">4@CSG8<5Q+H4TPO6LA
M;@!=;A++6?0E20?Y&OT!7__1[&O\BOL:_+&F=+R=8:K5:H[J&-Q6XXXL9V)!
MYX]3R*[C8.EUNL=ANUG5-=F,71"4K[B`-A`.",?4Y_2N:],[I)T7U$>L-P.Q
MN4X8CH/@.`_(K]3Q]E5*=:M3.7.[QM)V\EP,K2I]*.=[JN$I_0']U?2JI-B7
M"XW>'H&U+_A17>TM(.$.R/+KBO<`@@>P2*Z(GH)9?PWMJNLSXW;_`)8!.S=_
MH8SC]:JNA;O=.G_4$Z9N+I,5Y\,.M@Y2%*_(XGVSD?H:U^EJ<]7!GC:9)Q^B
MJ_0]?F^7;E7#K1/MS;O95*GOMAS&=NX*YQ^M1,[2'P6OTZ4^.WYDML?$=O&-
MP'.W/IGWJ9U89VB(:]!P;GWVW7?B)3J$]LJW@!+9YX&!D\\Y%3L?H[8Q:$JF
MZMCM7!2,X2XWVDJQXY.3]ZQ=(M1S;'JQW2<R0'8KRUH;"5[D(=3GE)]E`'QY
MXKNM<XZY_P#,1K@_Y\W_`+JZJ%KU/<]+]%(TBUK;;>DW!U@N*3E2`03E/IGC
MUK5TETGGZSM7X]<;R8XE*46R4%UQS!P5*)(QR#[U@L$B[],>I*+*Y(#S#KS;
M3Z$$['4+QM4!Z$9!_<5M:TOMYZB:X.F+0X1#:>4TVV%$)64_F<7[@8./I]34
MI)Z`NH@;HU]2Y,`SL<8VMJ/MG)(_:NRL([4=ML^4("?V%9*4KD>L^GEOTK;[
MAJFQ.S47!*@6&T*R&5+4`HIP,^"<<\5IP>F=QG:8C7F=K2;$0[&$AY#J%$-#
M&3R5^G/I4[H#J18QI^);KG,,-R/EAI^4<)D!/]K/IP1D'U/DUH:VUG:-72;=
MIJW7-R+'E2<KNB0>V%`$!`&03DD9/`Y'FH;5&@[[H:T-WF!J67*>:?2A+;31
M21G//YC[>U7;2?3"S6>[1]1I7(5)4V'$,+(V,K4GYL<9/DXSXJ].MH>:6TXG
M<A:2E0/J#YK\U2&[GTKZA=Q#94F.LEK=PF0PKTS]N/H17;[)U)TK?(R76[JQ
M%=*<J8E+#:T>_G@_I6U"UI8+M>%VBVST2Y*6%/*+/S(2D$#\WC//@5QWHN0K
MJ1((Y!C/$?[2:_0-<2ZXZ=7#N</4\-)0'L-/K1QM<3RA7Z@8_P!45']']/OZ
MCU<]J*XJ6^B$KN%QPY+CZO&3ZXY/[5__TJY\6=`]9WY=P0OL"4XM2L9):=SA
M0]\!7\C7=4ZEL2K>9Z;O",4)W%WOIP!^_P#*N$/RAKWK,U)MJ%EA<IHI5C![
M;0&5_3(3G]17CIK<(D/JF)4N0W&949'SNK"4C(5C)-=W<U7IUIM3B[[;@E(R
M<2D'^XUQ2+@_T@B0<@W19!_0TO:2?Z0*``2?Q*/_`'(K7ZSVUV)U`<E/`AB:
MTVM"\>P"5#[C'\Q4S;NB$2[06IT#5;;\9U.Y*T1L_P#RX^U;^F^DD:!>6+M"
MU8S(_#)*5.A#`P"G!*2=W'!_G748E_LT]Y+,.[0I#J_RH:D)4H_8`YJB]=7-
MNB8R.?GG(\>.$JKG4[_H/MG/_6[G^ZJNP=*0!TVM&/5"S_[BJY7U.!/6%L`<
ME47'U_+7S14V-HOJU,8O"@R@K>C%U?A!4H%*B?8X'/UKOK\V+&B&6_)::CA.
MXNK6`G'OFL4Z\6RV=KX^X1HO>.&^\Z$;_MFML$$`@Y!\$5]I2N*:TAZT%R?T
M[+U/`=@W9[N(2Z\AM:$[LA.T_,!XX&0<5I])K+;+YJIZ;*<9+5L1VXD)PC>O
MS\Y3ZXY)^I^E06I=+QHFNI>G+7+CK9D$O1U%["8RL%12H^!C!'/I@UT?IPYK
M&\SV[I=+]$>MT5HQS&8<2YW#C@JV\`\`Y)S^]=-I4-J;2EIU;;_@[K'W[>6W
M4'#C1]TG_AXKED[H#+#Q-OOC"VB>!(:*5`?<9S5BT+THD:0O)N;MV:D+5'6R
M6T,D`%6,'.>?%9]%]*U:/U'^+IO`E!32VUMF/L_-@Y!W'U%=#KB'6_4BY]VB
MZ7A**TL$./I3_:=5^5/Z`_\`JKI^A]-HTKI6);,#O!/<D*']IQ7*OV\?85AU
MEH2TZTB(1,"F)37^2E-`;TCV/N/I7-O\`%P^(Q^/1NSG\W95NQ]LX_G71M'Z
M!M6C(C@@DO374X<EO#YC]`!X3GT_G5">Z!/.O+<_K&CYU%7^:>_^M7@?T?WP
M01J)O(/_`'4__JO_TYN%TIFQ]<-ZH>O;+CJ9/?4RF,0#Z8!W>U>IO2V=,Z@'
M5?XRR@B4A]#/PY/"<823N]AYJUZMTC;=8VKX&X!2%(.YE]'YFE>X]Q[CUKE"
M^ANI8[JFX=[B=A1\E3B"1]4@'^^KQIW3[_3GI[=T3)3,E:$NR`6P0G\@`'/U
M'\ZK_0_2*8\)S4\ML%V1EJ*"/R(!PI7ZGC[`^]7'J#H^1K6SQ[<Q-:B);?[J
MEK;*R<`@`8(QYJMR.DLU[0L330O#`,>8J27^P>01@#&?J:NFC[`YIC3$2SNO
MHD*C;AW$)*0K*B?!/UJIZKZ7S-1ZS3J!JZLQP@M%+2FBH_)CUS6_KWIC`UFH
M36GO@KDA(3W@G<EP#P%#_C_?7/V>B.JR^EIZYP1';4"G+RU`X]D[>*MO4?IA
M<=87B)/@W!EL(9#+C;^<)`).Y.`??Q]*O]GMXM-FAVX.J>^%80UW%>5;1C-;
ME*5S;6724ZJU8F\HNWP[3H0'VR@J4-HQ\ASZ@59VM":=8U(UJ!B`EJ<T",H.
M$*)&-Q3XW8SS]:C)/2K3GX-<X<"/\-)GA7^-*)6MO)W`#/A.1C`\BOG3CI^Y
MH=F:9$],IZ6I.>VDI2E*<X\^3R:NU*4I2L4E3Z(KJHK:''P@EM"U;4J5Z`GT
M%<ITMTMOC.N!J+4KL-\!U4@I:<4HET\@X('`//Z"NMTI2E*^9&<9K[2E?"D*
M!"@"#Y!K_]3LB4I0G:E(2!Z`8K[2E*4I2E*4I2E*51-6HGRM1R68,69+<9M2
M7&TL3C'#+A6O"\9`4>/KXJ0CZF[<%IQA"ILAZ/#2TMQPH2\MW<`2/['@DX'T
M]JQ3]1WU#GP+,>$Q.8N$=AXJ<4IMQMSD%)QD$X((/BO3>MWGK^J"S;''8[<S
MX-Q:$.%25#\SGY=NP'C\V?6M2\WF[7;14NY-PF&HCZ4+BXD*[I_BI"=PVX&[
MZ'BMYW4]X8<=@+ML15Q1,98`2^KM%+J2H*SMSQM.1CTKVQJ6Z3$L0F(,5-R6
M[(;<#CQ#*>RH)400-QSN3@8]3GQ4>=5)^.1=W8JDKCVZ0E<<.9'<3(0V0%>,
M;A^;'BM^3JJX6UYZ!.MS!GX8,<,/DM+[KA;3N44@IPH<\<CQ7D:AFF8N!=(;
M33\:=%9"HTA12YW,D'P#@8_*?-8K;K>7<I"5Q[,\]%>0\6>VA>X%O.`HE(1\
M^"!@G!(J5TS?'[Y!><?:89DM+VK825[FB4@[5A200>?L?(JOZ;N5U:8#+<*"
MY<KE,ENK<4\H(V-N;25'!).2$I`'CVJ5MVJ)UVGP8T:W--AUMU<I3KQ_A%MW
MMJ2G`^;GP>*C]57.;:=:VR:W*4BWQHBUSF<G:6U.)05X_P##N"L^P-:,75LJ
M'<;Y?I;CDBWKBLNP(J"<!!=4VD_3>1NS[$5,QM927TF.+63.5)3'9&Y:&72I
M!7N"U(!P`E61CR![UKP+Q+1?)+=SCN1W5W1#6QJ05-I`C;L^.4G&<8')'M6X
M=13I%D5=7K:&;>\EM<=3<O#J@I:0-PVX3D'/!/M7MG4\Q=S+3EK2B#\>N"E\
M/Y65I!(5LV_EX(\YK!8];)O\UN.Q!<0S);<4R\DJ)3M\;\I`3D<C!/M4.;)K
M\M*:BW!#"%,*9W/R"MPG<5!WC("^`GCC"L\8Q7__U>QHR$)"O..:]4I2E*4I
M2E*BKCIJTW69\7,C+6\6NTHI>6@*1G.U020",D^?>LS]DMDEAUAV&V6W4(;4
MD9'RH_(!CQC/&/%8!I>SBWN0?A5%IUT/+47EEQ3@QA6_.[(P,'/I7M.G;6FY
M?B"8Z@_O"SAU>TK`QN*<[2K'J1FL:-*V5M;JDPOE>SN;+BRV,J"CA&=J<J`/
M`%;AM<%4M4M49!?6M"ROG)4D$)/Z!1_>L$K3UJF("7H@REU3R5H6I"TK5^8A
M22",^O-?4:?M#<<1TV]D-)CF,$;<CMDY*?U/-:;^EH+-JEQK=#CJ<DA(7\8I
M;H6$G@%1.X`>F#P>:UK!I%FWJE/S66>Y(DMR$M-N..);4@82=Z_F4KR>?I[5
M)-::L[,EV0W#"5O!84.XK9\_Y\)S@9]<`5FMEF@6=#B8+)1W2"XI;BEJ5@8&
M5*)/`X'M6&1INTR8S<=<3:AIQ;K9;<4A2%+)*B%)((R2<\UL1+5`@EDQ8J&N
MPSV6]O\`902"1^XS7V3:X,UQ;DF,AU3C"HZBKU;5C<G['`K`[I^U/-N-N0T%
M#L=$9202!VTDE*1CQ@G@CFL2M,6QR$8CHD/`NAX.N27%.I6.`H+)R"!QQ7J%
MINUP#N8865F1\2I;CJEJ4[MV;B23GY3BO#&E;1'2XVVR[V7,?P5/K+:,*"_E
M23A/S`'BMQ-JA)``8`Q(,GR?\H<Y5_,U@MVGX%J?+D0/H3R$,E]:FFP3D[4$
MX3D^U2=*4I2O_];LM*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4K__U^RTI2E*
M4I2E*4I2E*4I2E*4I2E*53VM>I8UR[IBZ0DQ0I6V++2X5(=5@*V'(&%84/4\
M_<5/66X2[@W*7*8::[,IQA';65;P@XR<@8Y]*DJIURUC/BZV<TZTQ;VVTQ/B
MC*DR%("4^,$8\Y^OBK1;W9#\!EV4EE+RTY4&5E:/T)`R,5L*SM.W&['&?&:Y
MS)ZE76+9+W-=M402;+-3'?CE]0W))P%@X]3Z>U6Z)>9$ZXP6HR([D9Z$)3[H
M4K*-WY`GCG//G_LFIFO_T.@:RU9_5=%N3L:3\?)#!D/Y[3`\E2L<_IQZ\\5-
MV]<MR*%3%1EK))2N-G8M/H>?'[G[UM4I5:UQJ67I>UQ9<-AB0Y(E(CAMXD9*
MLX((^U>]+:CEWN7=H<R&VTNV2.SWV%%33W^CGG(]1]:L55/4NJYEFU3:+-'1
M#V7)*R7I"U)[6WDDX\YJ?M$IZ;;T27G8KP<)+;D4DH6CT(S6[57L&II]XU9>
M[2Y&CHC6I:4=Y!5N<*N0,'@8P<U:*U[@^Y&MTF0T$%;32EIWYVY`SSCTJL:1
MU;<=3P8$U;5M83**U*CB0HO)0DD;@,<\X]N#5OK#,ELP8;LM]6UIE!4H^O'H
M/K4'HC5"]661V>[&$5UN2XRIG)RC:>`<^N#S5BJM:OU:-,NVQC8TDW%\M?$R
M"0RP!Y*L??@<?>INWKF+B[IOP_<W'"HZB4*3Z'GQQZ<_>MJJ6-:3W-47FS);
MMD=%L2@A^3(4D.%8^4>.#[^:N+1<+2"ZE*7"D;PDY`/K@U[I5-FZ/7J2Q72%
M=8Z8LEZ:Y)BOH<"RVK@(5D>.``14UI2VS+1IF'"N#G=F(252'-V[<M2BI1SZ
M\FIBJ$O3]X_KY=[Y(LD:?$E1DQF&G)"<A(QDD$'&<']ZN\3N_!L]]E#+NP;V
MD*W)0<>`<#(%9JI4SIZS<-87:Z25@PKA#2V6`>"]M*=Y'T3X/NHU)Z&TV]IC
M3;$&6_WYF/XSFXD<<)2,^@&`*L50>I(LFY1'[:JRLW&&^R1\[X04KY\@C@>#
MD<CVIHRQ2--:4A6F5*^)>CI(4L9P,DG`SZ#.*G*4K__1NNO=,7#5"[0PPU'=
MAQ)8D24/.E!<`XVC`/H36QHFP773#$NT27&'[:V\I<%Q*SW$H4<[%`CTSYS[
MU:*I]WL-WE=0(5_:B1)$.%%4REIQXI6I2LY5^4@><59K:E]$!M$B,Q%6G([,
M=6Y"!G@`X'ICTK:/CBJ1IRR:DL,Z^S%0H+[UVF&0C_&B`V.<`_)DXSZ5=AG'
M/FH[44>;,T[/B6]*%2I#"VF]Z]J05#&2?IG-0NC[/<;';;7;I%HAH,1@MO3$
MOA2CGD[1MSR<>35LJ&O5OEW6="B*:_Y,2OO2%I?*%E2>4``<X"L$\^@J(T7I
MRYZ<O%\2\VW^'3I1D1SWRM:2?(5D>O'.?2KA5>U3#E7:%*M:[&S<8C['R*4^
ME!2YSY!\8X((R?/%9](661I[2L"U2Y/Q#T9O:MP$D>2<#/H,X'VJ:JAVG3UZ
M@7G4%QEV:#-5=)*76$KD#Y$ISM"LI^QX]JO:=VT;L;L<X\9K[2E*4I2E*4I2
ME*4I2E?_TNRTI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2O__3[+2E*4I2E*__
!V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>cryolifesyner2.jpg
<TEXT>
begin 644 cryolifesyner2.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#__@`<4V]F='=A<F4Z($UI8W)O<V]F="!/
M9F9I8V7_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-#AT5%A$8(Q\E)"(?(B$F
M*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_P``+"`!'`<`!`1$`_\0`
M&P`!``(#`0$```````````````,$`0(%!@?_Q``X$``!`P,#`@4#!``%`P4`
M```!`@,$``41$B$Q$T$&(E%A<10R@14C,Y$D0E)BH0<6@E-RL<'P_]T`!``H
M_]H`"`$!```_`/LM*4I2E*4I2E*4I2E*4I2L9'&:S2E*4I2E*4I2L$@8R>>*
M_]#[+2E*4I2E*4I2E*4I2E*4KA>+FWC:6WV9<A@L26%%+*]/4RZ@84>2,$[=
M^]49]XF-^)G92F%*M5L*([FE[2HO.Z?.48\P`4D#?NHC-;1V';;XC4N6`Z+B
M^\(\A,QQ73\I5I4V?*``D[CC'O6WA9EVUR3:IK>J7]*AXR42W'DO#."2%_:<
M[[;'/M7'EN35^+I#;:)#74N;33<\S5!MH!IM9;+7!U#4!D8)57;1XAFN+1(7
M%83;Y$M<-O#AZP4%*3J(QC&4G;D#>N99/$4^U>&+6_<(\=V,Y"4ILQWBIS]M
MLK\V=CD)/'!P*ML^*KLY!6Z;2GJK+'0*^HTVHNKTZ25)SE.<Y`P161=_$S$V
M[H<BQ)?TC+):9CZLZE9R=QN,9..=L#FNHU<5SO##\OJ-]4,NA19U)"5)R",*
M`4""-P=P:\G:;A(\.D2),5;*%6GKHC"<J0'UI*<K45?QGS#V.3Z5Z']>N$.4
M85Q9B*?S'4%QUJT:7'.G@YWR.1Z^U5;A?!^J)DJ:U(MDB2@I0K)<"8X7_>Y'
MXK,3Q3<S"<F3;:E$=M#3ZG0E2$I;4K"ONW)2/-D;$9XK2X^,9+%N,V(RRZ`A
MZ0AL(6LN1T'`7D8"0K<Y/J-C4ZO$EQ49KK<:*&&I+41@K6K)6L(.I9X"1KX&
MYQVK_]'Z)8'92K_?$SEQU.H6PG+!.G&C(R#N#OQ\5%XH8FR;S9V[?,7&D(#[
MK8"L(<4E*<)6.Z3D@^F<UR57L29<R]AUQANUOQE2F%*.6!I6AY*AQL%9]](-
M1QI,S4F"])?+GB5UN6RDK.6D:LNI3Z`-!'Y4:^@5Y;QC=?%=ME6M'ARTMSFG
MGL2E*&=`R,#D8!R=_:O4UYKQB_=&#:E6A"7)1DK"4*5@*'1<S[$CD`[$@523
M>DVZ+;XMA2Y,5.#SSLB0E3B]:-.H+3E)"LJP1MIQQ4S_`(CO*6'I?TD2.U#A
MLR9#+JBI9*]6I`(.!@)V.]647RYBYDN-Q!!_4#"2E(5U3Y<A><XYVQCCO5"!
MXJOMPC+DL6ILH=CN.L!S#82H*`"2HJ\V<G.R<$8[UO-\6RV+.'HZFGYK*'G'
MV1%4G`;."""L:,$@$Y/.V:2O&SL:2&U1&]+91)DDJ/[,-24_N^Y"E$8]$*KT
M=IF.3[:Q)?0EMQY`<Z:3]J3NG_C'YS7EUL1)D2[39T6-.N<:0Z%,R7RWT6TG
MR!)P=`*,*!`W)YJ1SQ9<7)"$6^V%;:(T=]:%#)6'>VLJ`3@=R#DU;1X@GJDI
MD%,7Z1=P,(1AGKCS%&LG..1JTX^W?-11;]>9,:VEPV^,Y<NHXE:DJ4AM"0,)
MY&I9SGD``'G%11?$ZG(_U\H1$NIC2/WV=;B#H?#:<#.X)P?_`+KJ^&[O*NB)
MS<QH(?A2>BHA.G5Y4J!*=2L'S8QD\5YV\ENW3Y+UKZ;;<J!)*'8CQ6XZL%*E
MJ6.VD!6DY.Y(VV%=6%`@?JTNV6UQ34%V"VIP1G2`E14H!04#LI21N>2`#7/D
M2'$>`[="2B<6)$10??C(4XM"$IXR,D%6PSZ9JG=;LY(M%E4MFZ-QF$0WPMJ.
MX>LX7$C"L#@`'8\E0]*^A`Y`.^_K6:4I2E*4I2E*5__2^Q.LMOMEMYM+B"02
ME0R-CD?\BJKUGMTB>B<]":7)1@I<*=\C@^Y';TK#5DMC$QR8U`82^[JUK"-S
MJ^[^^_K6UOL]NM06($-J/U,:M`YQP/@=AP*D<@1'DN)<C-+#KB7%@I'F6G&%
M'W&D;^PJ)-FMJ;@;@F$R)1)/4T[Y(P3\D;9YJ.'X?M%O=+L2W1V5%)1Y$8`2
M>0!P`>^.:VBV.UPD*1&@LMI4I*B`GNDY3_1X]*S*LUMFON/R8;;CCC8:6HC=
M20<@'X.X]*FCP(D2&(<>.VW'`(Z:1L<\_.<FJ\*PVBVH<1#ML9A+J="PAL>9
M/H?;VHS8;3'B/1&K>PEA_'51HR%XXS\=O2I8UJM\-"41H3#24J*@$-@>8C!/
MR1L3WK6+9[;";>;BP&&4/C#J4-@!8]#[;G;WI(LULEH9;D6^.ZAA.EI*F@0A
M.,8`]/:IEPHKC+K"XS2FGOY$%`PO8#<=]@/ZJLBPVQH-)8AML):>#P2TG2%+
M`(!5CG&>_M5U33:G$.*;25HSI41NG/.#4:H,18?"HK)$D8?!;'[NV/-Z[;;U
ML8S!<:<++96R"&U:1E`.Q`].*EI2M5-H6I*E(2I2#E)(R4G&,CTV)JM(M%ME
MMK1(@1G4K7U%!;22%+QC4=N<;9J;Z6/H4CZ=K2I(0I.@8*1P#["L]!G_`-%O
M[]?VC[O7Y]ZK"SVL+?6+=%U21AX]%/[@_P!VV]8-EM18:8-MBEIG);064X1G
MG`QWJP8D9143':.IOI*R@;H_TGVW.WO6K,*/'E/R6T8=?"0LY[)&$@>@&3_=
M1R[1;)[R7IEOC2'$?:MUE*B/R16[]M@27FGY$*.ZZS_&M;8)1\$\4%O@B=]8
M(C`ED?S=,:\<<\^U5[G:C.BMQV'&&6VU9Z;D9+K:AC;RGC'.U9M]FB0+:B$6
MT/)"5!:G&T^?4=2M@,`$GCBK$)B$Q'`@-,-LDY'02`DGCM6&;=!C/N/L0X[3
MSW\CB&DI4OY(YK:+"BP4%N)&9CH4=12T@)!/KM4J6T(;Z:4)2@#&D#`Q\5__
MT_L?31H"-"=(QA.-ACBL@@D@$9'(]*PAQMPJ"%I44'2K2<X/H:VI2E*4I7DY
MH1(\./S7R^[+?E.(C-ID+;PX5EM"?*1L,#/P36UWM#:6+1;$29:YSA;9^H$I
MQ*@VWA3BS@X)(&,GNH5$XM9=<N9DO?6)O`B!'5(3TBL(T:>-T'5QG)SFNM`N
M"XOAIZ4^'9*H1>1L"I;H;6I(^20D5Q_"TE=V3?82KQ*<?,A*U.H"DED*;02E
MO4GR@'4!MGO[U5<<D'PE9;G,1*N$)F!E]MJ26W%ND)T*)U#4>1C.<J!WKT5N
M4Z;+'MUV=>$PQ$_4.IU)P2,']P;:O<'/>N7;(Z7?U>U26WVNB^A;,/ZU1!24
M>7#F<X44J)3VJFQ'G3[+$<*BZ;<Y*3*B.3G&E`A6R`XG[](V!.QV-69JUB4Q
MXB+:G[:6(VEGZQQMQC*CYM`\JON3D$Y.*O>+NNLVEAEIUX/3=*V6I)8Z@#3A
MP5#MD`X[XKE,B_VFXL(`9><1!D/*1(D+6&V^JDH;UXRH@;:CZ=ZZ#OBJ6N/(
MG0X3)APH[<B0'G2EQ06@+P@`8R$GD\G;WJ2/XBGO3@I<)E$%4Y<)*@Z2Z2`<
M+QC&,C&.:U\.^)YE\D-*5;7&XDAM3C3NA8",$8"BH`$D'_+Z5Z6O*JOGB4?]
M0Q9TV0&R='49V#SISG5Q]WET\]Z]57$D(8E72Y?J#A$2-&;!1U%)"02I2E'!
M_P!HW_VFN,W!BQ_!CLR7&>>,ITR(L5;[F0IS"6F_NSQIR/4FCUJ8CI7;YTQX
MIM=G0XRX7E`I<RO6[G.Y&E//'YKL>'WY#DA]+ZB2Y&CR%`Y\KBTD*'M]@./<
MUQH]Y3)\<H,A^;'ZL>2PB.MIQ"&TH4C"\D:<GS'5G8:1\Z,/K@V^;<K`E28S
MZ&HL(R'2I,AY2](?5G.$Y4-^58SZ5VK'<3&C&V2([QD0G4QG%-%3X45)"@LJ
MQD`ZM\@8KSDIYZ'9F+M%?=%UE+E)?4%DDA*'21ISCR%*<>F/>NJQ"MS%S7;6
MWBJ!)@-N.H4^H!;A7A"M6>5[@^N.]4RRXYX(O\5QY^&["<?);C2#AK"-:4)7
MR4X()&VY(XKT%\6H>#9[@40K]/<.H'!SH/>O_]3V\!"[!:5/IMD6WR))::9Z
M+BY/64>VG"=^>_YJ)?C:8U;(4A4-DO2778ZTE1`84AS1U5X)PV/\V^Q(&:]D
M,Z1D@G'(KSGCBX^)+;96WO#%O1-EEY*5I4G5I1@[@9&=\#\UWH:WW(3"Y3:6
MI"FTEUM)R$JQN`?8US_$=V>LUM0_'CE]YU]MA`QD)*CC)&1GXR,[5I:;Q,D1
MVA<+<^V\MY36IMKRX&,*(R=`.>">QKE,WWQ)(CQWTM6QM$F&[*3D+44!!3Y3
MOOD*&^V-^:D=\6O=6"ZPVA<=XQDOHZ9RT7L8\^0,X4#@`_BHK9-4_=6WF`S'
M6(,D)#BE*0"F3IR23GMFNY>GPP(!+27-<UI`U*(TDYW&.3[5YZ5>[S+L+A=^
MB;-PMLAYDMH6>EH`V)SOD*YVP1WJ87:?;H3C$86YEJUP6GG$K04];*22$`'R
M#;&=]S[5R;Q*>ES)ZWQ)0^VV%L)$7K8!/E!!!"4A.%$C!)4=_+BNU;+E/*8M
MOC260E,8R`_-RM3C9<*4#8C<)`U'MD5.;]/CL2;C+3%3;X\Y3"].K4AI*R@N
M*.<;'!(QL,U&/$%SDIU-?0Q`F)]9_B=7G;*E:!R,>5(*CO@J&U5F;@9%T3+2
MPD*EO1"$N$Y9*F%D';&2.,?-4+;>[I;;5;X4=AEZ0^U(E./)9\JBES&""L;[
M[JR<>E>GGWA]BTQWD(9:E/J90M+J]2(Y<(W5@[@;@>IQO521=;FW*3!3.MJ'
M&HRI#DEU!"'<*(TA.K;&/,<G&1M517B.]2V%RH3,-EMMJ*OHOI45*+V,@D$8
M`R"-CGVKN6B7*?5-CS5-+>B2.EU&DE(6"A*@<$G!\V.>U=*E*54:MD5I95HU
M_OJD("]PVLC!*?3DG_R-3EADR!(+:2\E!0%XW"202,^F0/ZJNJT6]5P_4#%;
M^KQL]C<;8SZ9QMGG%2PH;4"&U%9U:&Q@%1R2>22?4G)J1#3;:W%H0E*G#J60
M-U'`&3^`!^*C,**66F#';Z3*DJ;1I&$E/!`]JW?8:E,+8?;2ZTXDI6A8R%`]
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M9!N"VES(C+ZF3ELN(!TUNQ$:CO2'D:BN0L+65'/```'H,#_YK=UAE[/5:0YE
M"D'4D'RG&1\'`R/:J,?P[98C;K<>UQ&D/)T.)0T`%)]"/2K<.#%M['0AQVV&
M\YTH3@$^I]36C=K@,S79K<-E$EX8<="!J4/<U&U9+4S&>C-6Z,AE\ZG6PT-*
MS[C_`/8J5BWPHT0Q&(K+<=6=324`)5GG([YJ93;:VRTM"5(4-)01D$>F*CD1
MXDIOZ62TTZA0STE@$''?'M6K=N@LH*&H;"$*04%*6P`4DDD8],D[>]6$I"$A
M*0`D#``["LTJ-^.S*86Q(:0ZTL84A:00?D&L1HL>$PEB*PVPTGA#:0D#\"LI
MCLH2E*66TA*2E("0``>0/;:H56R`I]#ZH4<NM@!"RT,I`XP>V.U2&'%4DI5&
M9*2DI(+8P03DCX)WJ1;:'-.M"5:2%)U#.".#\UI]-'T!'0;TI24!.@8"3R/@
M^E1OVV#*<:<D0F'EL_QJ6V%%'QGBLR($.8I*I,5EXIX+B`<5B3;H,P-"3#8>
M#)RWU&PK1\9XJ*Y6T3X*X25I89>5^^`V#U$'[D^Q/KO4LFW09O3^JAL/](Y;
MZC85H^,\5,66BO66D:L@ZM(SD<&H7[=!E-(:D0V'FT'*4.-A02?4`U(N+&<2
MM*X[2DN)"5A2`0H#@'U%0JM-M6PVPNWQ5--$EMLLI*4$\X&-JL%EHYRV@ZL9
M\HWQQ_5;!*4E12D`J.20.36:_];[+2E*4I2E*4I2E*4I2N'XN6^BR(5%"2\)
MD;0%**03UD;$CM5-V]7I<N+&:$)MUNY?2RLE12M/2+@T]QL1^1Z5&B^7YD%M
M;<!]V1=5PV"5J0EM`2HY5MN?+L.^:ZMNNDJ2'4R4QFE0WU,R5)62D@("@4?V
M,@\8-4&%/SFHB-:TN7209C@R04,)P4I]L@-@_*JI_P#?JNJ4&"GRI,=1ZG$[
M.`QQZ;YJ:9XX%OFN,28B0W#6M,]P.?P9_A.._4_XS6KWC5Z%(1&FP6T/-J0Y
M,PYM'C*2G]TY&^%JT_\`BH]JZ+E^DFQPI;<=I,F>XAMI#BSH1K)TE1Y^WMW.
MU%W"^">F`VS`6\B*7W5ZEA*CJ*4I2.V<;DG;WJHCQ:[/;;-NCM?O.M1DK>4=
M+;RDJ6M*L?Z0`,=U'&U4YUU?D2V?JVFR]!7,:<#*U!MTAC5L>1LK!]"#O5<W
M>9;IMPNICQWE*9A,QFTI4I;74VP3G<9).W.!7I;-=9<N"\Y<8ACNM.J0D8T]
M8``Y"221W&">U4$WZZ&SQ[@4P")Y:3&0%*PSU#@=16=\>V-]JQ^OW95P1:FV
MH2I8DJ9<?\W2P&@X"$YSG?!&??-3V:\W25*AMW%B*V)L9QY"6%*)04*2""3L
M<Z\[8Q[UZ"E*_]?[+2E*4I2E*4I2E*4I2E*4I2E*4I2E*4K1UEI]`0\VEQ(4
M%`*&1D'(/X(!JO(M4"6E27XC3@6Z'E93RL``*^0`!FJ5P\+VRX26WG([0Q($
MAY.C(>4$*0,^XU9S[5;19K8W#1$1!92P@*"4!&PU`A7]@G/S7__0^PICLI?Z
MR6DAS0&]0&^D'./BH_H(>_\`A6=W>N?VQ_)_K_\`=[\T<M\)TO%R(RLR-/5U
M-@]33]N?7':LNPHKZG%/1FG%.M])PJ0"5HW\I]1N=O>M7K;!D-.M/1&7$.I2
MEQ*D#"@G[<_';TK#-OC0V=$%AEA24%""$;#<G?U&3GFJT.Q1&+2JWR6VY2'5
MJ=?*VP`XXI14I6.VYV]-JLM6R`PPVPU#80TV%!"`@82#S_??UK9<"&XTXTN*
MRIMU(0XDH!"DC@'U`K6-;8,-IMJ-#9:0THJ;"$`:5'DCW.3O4:++:FP^$6Z,
MD21AX!H8<[[_`)WJ6+;8,)IMN+$990T2I`0@#23R1[FI4L,H4A26D`M@I00D
M>4'&0/Z']5)2E*4I2E*4I2E*4I2E*4I2E?_1^RTI2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2O_]+[+2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*__T_LM*4I2
..E*4I2E*4I2E*4I2O_]D_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
